AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01784991
Drug: Usual care group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
Trial: NCT02972294
Drug: Placebos iron isomaltoside 1000
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
Trial: NCT00543816
Drug: MK0767
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02239913
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
Trial: NCT01731275
Drug: E6011
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
Trial: NCT01731275
Drug: E6011 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
Trial: NCT00807937
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets and 1 capsule taken twice a day for 28 days
Trial: NCT00807937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets and 1 capsule taken twice a day for 28 days
Trial: NCT00320632
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02502708
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered orally daily.
Trial: NCT02537483
Drug: IDP-120 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product: IDP-120 Gel
Trial: NCT02537483
Drug: IDP-120 Vehicle Gel
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator Product: IDP-120 Vehicle Lotion
Trial: NCT00122824
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03140514
Drug: Rejection treatment according to clinical standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
Trial: NCT04264858
Drug: Immunoglobulin of cured patients
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2g/kg, ivdrip, once a day, for 3 days
Trial: NCT04495322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
Trial: NCT04453618
Drug: Placebo-25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT04453618
Drug: SYHA1402-150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 150mg, oral tablets
Trial: NCT04453618
Drug: Placebo-150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT01951326
Drug: RHB-104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
Trial: NCT01951326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 placebo capsules administered orally BID
Trial: NCT01773616
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01017185
Drug: HF10
RxNorm normalized name: Hydrofluoric Acid 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02558972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
Trial: NCT02558972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
Trial: NCT03725566
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
Trial: NCT02153632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects are given an identical placebo tablet
Trial: NCT03353675
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance
Trial: NCT00039546
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01128049
Drug: Instill Saline Drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
Trial: NCT04312815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 600 mg intravenous (IV)
Trial: NCT00779636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily x 28 days
Trial: NCT02372253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02260934
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
Trial: NCT02260934
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
Trial: NCT04292535
Drug: Placebo into the intranasal mucosa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer
Trial: NCT03991845
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit D supplementation was done
Trial: NCT00847834
Drug: Irbesartan 150mg / Hydrochlorothiazide 12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day
Trial: NCT02318134
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline via a nasoduodenal tube.
Trial: NCT00640549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
Trial: NCT03692780
Drug: Careseng 1370
RxNorm normalized name: LANCET,CARESENS 30G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4,000mg granules in sachet
Trial: NCT03692780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4,000mg granules in sachet
Trial: NCT00378534
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Therapeutic
Trial: NCT02545738
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04135885
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
Trial: NCT02922725
Drug: 5-hydroxytryptophan and Creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01431612
Drug: Lactated Ringer´s solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
Trial: NCT01071044
Drug: Placebo 30, 50 or 70 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
Trial: NCT01450228
Drug: KI1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged release melatonin 2mg
Trial: NCT01450228
Drug: Placebo KI1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo KI1001 tablets
Trial: NCT00058318
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
Trial: NCT00089544
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01782170
Drug: Iocide Oral Rinse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01782170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01111513
Drug: Patient controlled analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled analgesics alone, no femoral block
Trial: NCT02134951
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be used for placebo in this group
Trial: NCT01557335
Drug: Plavix® and PA32540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
Trial: NCT03504423
Drug: CPI 613, mFolfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
Trial: NCT03504423
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folfirinox
Trial: NCT03702023
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group will receive 1000 mg of acetaminophen
Trial: NCT03702023
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group will be given a placebo capsule.
Trial: NCT04249076
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
Trial: NCT03137992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
Trial: NCT03137992
Drug: Test Product (tiotropium bromide inhalation powder)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-Blind: Single dose of test product 18 mcg of test product Open-Label: once daily administration of test product (tiotropium bromide inhalation powder) 18 mcg administered by test dry powder inhaler.
Trial: NCT03137992
Drug: Reference Product (Spiriva®)
RxNorm normalized name: Spiriva Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (Spiriva®) 18 mcg.
Trial: NCT01300728
Drug: NewGam 10% IVIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.
Trial: NCT01253291
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously every 4 weeks for 48 weeks
Trial: NCT02446028
Drug: BIOD-531
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02446028
Drug: Humalog® Mix 75/25
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00585052
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin, 80 mg, po, daily will be self-administered by the subject.
Trial: NCT02106845
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
Trial: NCT02015520
Drug: Placebo (Matching with Clazakizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01863485
Drug: CM082 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM082 tablets taken orally once a day on 28-day cycles
Trial: NCT02813369
Drug: non-PAMORA laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
Trial: NCT04076540
Drug: AZD4041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by Oral syringe
Trial: NCT04076540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by Oral syringe
Trial: NCT00129376
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01636687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 injections of placebo to secukinumab 150mg per dose
Trial: NCT00129376
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02949583
Drug: Punica granatum Linn.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
Trial: NCT01318655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, Once daily
Trial: NCT02999022
Drug: Lactose Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
Trial: NCT04034771
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill manufactured to mimic melatonin tablets
Trial: NCT00857116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
Trial: NCT04065139
Drug: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
Trial: NCT04065139
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
Trial: NCT02330926
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00975715
Drug: TRI476
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRI476 oral suspension doses, based on body weight twice daily
Trial: NCT00975715
Drug: Placebo to TRI476
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension, taken twice daily
Trial: NCT01973816
Drug: Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
Trial: NCT01973816
Drug: Cyproterone acetate 50 mg; estradiol 0.5% percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake for 18 months
Trial: NCT01973816
Drug: Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake during 24 months
Trial: NCT01001975
Drug: Sunscreen Test Code: V53-028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
Trial: NCT01001975
Drug: Sunscreen Test Code: V53-030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
Trial: NCT01001975
Drug: Standard SPF 4 Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% Homosalate Standard SPF 4 Sunscreen
Trial: NCT03817476
Drug: BI 425809 (Treatment R)
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial formulation 2 tablet (TF2)
Trial: NCT01404598
Drug: naproxen 500 mg bid
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg bid
Trial: NCT02005211
Drug: AZD3293
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT02005211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT00377182
Drug: RO5024048 1500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg po bid for 4 weeks
Trial: NCT00377182
Drug: RO5024048 3000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000mg po bid for 4 weeks
Trial: NCT03427632
Drug: Bone Cements
RxNorm normalized name: Bone cements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
Trial: NCT03482011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02607865
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once-daily
Trial: NCT01657253
Drug: PRO-148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill 1 drop in each eye four times a day, for 60 days
Trial: NCT03777696
Drug: placebo to TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 110 ml saline iv
Trial: NCT02424071
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes